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Background: The anticonvulsants pregabalin and gabapentin are both indicated for the treatment of peripheral
neuropathic pain. The decision on which treatment provides the best alternative, should take into account all
aspects of costs and outcomes associated with the two therapeutic options. The objective of this study was to
examine the cost – effectiveness of the two agents in the management of patients with painful diabetic
neuropathy or post – herpetic neuralgia, under the third party payer perspective in Greece.
Methods: The analysis was based on a dynamic simulation model which estimated and compared the costs and
outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic
Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN). In the model, each patient was randomly allocated
an average pretreatment pain score, measured using an eleven-point visual analogue scale (0 – 10) and was “run
through” the model, simulating their daily pain intensity and allowing for stochastic calculation of outcomes, taking
into account medical interventions and the effectiveness of each treatment.
Results: Pregabalin demonstrated a reduction in days with moderate to severe pain when compared to
gabapentin. During the 12 weeks the pregabalin arm demonstrated a 0.1178 (SE 0.0002) QALY gain, which proved
to be 0.0063 (SE 0.0003) higher than that in the gabapentin arm. The mean medication cost per patient was higher
for the pregabalin arm when compared to the gabapentin arm (i.e. €134.40) over the 12 week treatment period.
However, this higher cost was partially offset by the reduced direct medical costs (i.e. the cost of specialist visits, the
cost of diagnostic tests and the other applied interventions). Comparing costs with respective outcomes, the ICERs
for pregabalin versus gabapentin were €13 (95%CI: 8 – 18) per additional day with no or mild pain and €19,320
(95%CI: 11,743 – 26,755) per QALY gained.
Conclusions: Neuropathic pain carries a great disease burden for patients and society and, is also, associated with a
significant economic burden. The treatment of pain associated with DPN and PHN with pregabalin is a
cost-effective intervention for the social security in Greece compared to gabapentin. Thus, these findings need to
be taken into consideration in the decision – making process when considering which therapy to use for the
treatment of neuropathic pain.
Keywords: Peripheral neuropathic pain, Post-herpetic neuralgia, Diabetic neuropathy, Pregabalin, Gabapentin,
Cost-effectiveness analysis* Correspondence: kathanasakis@esdy.edu.gr
1Department of Health Economics, National School of Public Health, Athens,
Greece
Full list of author information is available at the end of the article
© 2013 Athanasakis et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Athanasakis et al. BMC Neurology 2013, 13:56 Page 2 of 7
http://www.biomedcentral.com/1471-2377/13/56Background
Neuropathic pain (NeP) is defined by the International
Association for the Study of Pain (IASP) as “Pain caused
by a lesion or disease of the somatosensory nervous
system”. NeP can be a result of a variety of conditions
associated with impairing the functioning of the nervous
system, such as diabetes, multiple sclerosis, trauma and
herpes zoster infections [1]. It is a common condition with
an overall prevalence between 0.9 and 8.0% [1,2]. Previous
literature suggests that individuals with NeP were known
to experience more severe pain when compared to
non-NeP chronic pain sufferers [1]. Despite the plethora
of etiologies associated with NeP, the scientific focus lies
mainly on painful diabetic peripheral neuropathy (DPN)
and post-herpetic neuralgia (PHN), extrapolating any
outcomes on other causes of NeP [3]. Painful DPN is a
common complication of diabetes with a prevalence of up
to 25% among diabetic patients [3]. PHN is in turn the
most common chronic complication of herpes zoster
infection (10 – 75% of cases) [4,5]. Neuropathic pain has
been associated with impaired quality of life, reduced in-
dividual productivity and increased patient and healthcare
resource expenditure [3,6]. Co-morbid conditions include
sleep disturbances, depression and anxiety disorders
[6], increasing even further the economic burden to
the healthcare system. In a recent review, the average
pain severity associated with painful DPN and PHN was
identified to be 5.0/10 and 4.4/10 (Visual Analog Scale)
and the average EQ-5D values, for patients with severe
pain, equal to 0.2 and 0.26 respectively [3].
The anticonvulsants pregabalin and gabapentin are
indicated for the treatment of neuropathic pain. Treatment
with the third generation anticonvulsant - pregabalin can
be started at a dose of 150 mg per day given as two to three
divided doses. Based on individual patient response and
tolerability, the dose may be gradually increased, if needed,
to a maximum dose of 600 mg per day. Clinical trials using
pregabalin for both peripheral and central NeP, showed a
reduction in pain scores within the first week, which
was maintained throughout the treatment period [7,8].
Alternatively, the starting dose of gabapentin is 900 mg/day
given as three equally divided doses, increasing gradually
up to a maximum daily dose of 3,600 mg. Clinical trials
have shown that the optimal daily dosing for pain control
exceeded 1,800 mg [9,10].
A cohort study by Toth et al. [11] investigated the
utility associated with the substitution of gabapentin
with pregabalin therapy in patients with peripheral
NeP. Results showed that both previous responders
and non-responders to gabapentin had additional pain
relief of approximately 25%, six or twelve months after
initiation of pregabalin. Another study by Tarride et al.
showed that following a twelve-week regime, therapy
with pregabalin was associated with nine additionaldays with no or mild pain, against six additional days
with gabapentin therapy [11].
Along with the previously mentioned high incidence,
chronicity, maladaptivity and co-morbidities associated
with NeP, comes the significant economic burden to the
national health system. In an attempt to estimate the
costs associated with NeP, Dworkin et al. (2010) calcu-
lated the excess healthcare costs associated with periph-
eral NeP between $1,600 and $7,000 [12]. In the same
context, Berger and colleagues estimated [13], that the
excess expenditure of patients with NeP, can reach a
threefold increase compared to their non-NeP peers
($17,355 versus $5,715, 2000 values). When investigating
costs associated with painful DPN, Gordois et al. found
that direct medical costs exceeded $10billion per year in
the United States [14]. Another study, found that the
average medical costs due to PHN following herpes
zoster infections ranged from $760 to $1300 per patient
for the first year after infection (2004 values) [15]. Apart
from the direct costs mentioned above, another dimension
of costs, the societal costs from NeP also need to be taken
into account. Characteristically, in a cross-sectional
European study, researchers identified that 43% of patients
reported work absence and even change in employment
status and 17% were disabled due to NeP [16].
Thus, the benefit of treatment for patients with
chronic neuropathic pain is dual, including both the effects
of reduced morbidity as well as their subsequent contribu-
tion in societal and health care costs. However, the decision
on which treatment provides the best alternative, should
take into account all aspects of treatment costs included. In
this decision – making process, pharmacoeconomic tools,
such as economic evaluation, are deemed pivotal. In light
of the above, the purpose of this study was to examine the
cost – effectiveness of pregabalin versus gabapentin in the
management of patients with painful diabetic neuropathy
or PHN in view of the third party payer in Greece.
Methods
Study model
The cost – effectiveness analysis was based on a dynamic
simulation model [17,18] which estimated the costs
and outcomes of pregabalin and gabapentin in a hypo-
thetical cohort of 1,000 patients suffering from painful
DPN or PHN.
In the model, each patient was randomly allocated an
average pretreatment pain score, measured using an
eleven-point visual analogue scale, with 0 referring to
“no pain” and 10 to “the worst pain imaginable”, which
was derived from the actual distribution of pain levels in
a randomized, double-blind controlled trial of pregabalin
in patients with chronic NeP, defined as subjects with
DPN or PHN [7]. Following that, every patient in the
cohort was “run through” the model, which used a
Table 1 Percentage weekly change in pain severity
among patients with painful DPN or PHN receiving
treatment with pregabalin or gabapentin
Pregabalin n = 141 Gabapentin n = 193
Mean dose mg/day 457 2400
Mean total weekly reduction versus baseline in daily pain scores %
Week 1 13.7 17.2
Week 2 23.2 25.1
Week 3 29.9 29.7
Week 4 39.1 32.1
Week 5 44.4 33.7
Week 6 44.2 34.9
Week 7 45.0 35.8
Week 8 46.3 36.4
Week 9 49.8 36.9
Week 10 51.1 37.2
Week 11 53.3 37.4
Week 12 54.1 37.6
Data obtained from Protocol 1008–155 for pregabalin [7], and Protocols
945–210 and 945–211 for gabapentin [9,10].
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sity and allow for stochastic calculation of outcomes
taking into account medical interventions and the
effectiveness of each treatment. Three different health
states relative to NeP were adopted from clinical practice
for the purposes of the model. Specifically, days with “no or
mild pain” reflected a pain intensity of “0 to < 4”, whereas
days with “moderate” and “severe” pain were associated
with pain scores “4 to < 7” and “7 to 10”, respectively. The
randomly allocated pretreatment scores ranged from 4 to
10 (moderate to severe pain). As the patient progressed
through treatment with pregabalin or gabapentin, the
model projected the estimated efficacy of the two pharma-
cotherapies on the assigned daily pain scores, and, thus, the
“journey” of patients and the respective outcomes. Default
estimates, model assumptions and further description of
the model have been previously presented elsewhere
[3,11,19]. An outline of the model is presented in Figure 1.
The time frame of interest in the model was twelve
weeks and all NeP-associated direct costs were considered.
Several outcomes were derived from the above dynamic
simulation model. The number of days with no or mild
pain was the primary measure in the model, but also the
mean number of days with 30% and 50% reduction in pain
score were estimated. Other outcomes of interest included
Quality Adjusted Life Years (QALYs) gained and the
cost per QALY gained along with costs of medication
and NeP-related healthcare services.
Pharmacotherapies
In the model, the cost effectiveness of pregabalin at a daily
dose of 150 – 600 mg (average maintenance dose of
457 mg [7]) was compared against gabapentin mean dose
2,400 mg daily (900 – 3,600 mg). The two therapies were
considered to have similar side-effect profiles and there-
fore no discontinuation of treatment or added costs due
to unwanted effects were assumed. The efficacy of the two
anticonvulsants in reducing weekly pain scores (Table 1)
was derived from three randomized, double-blind, con-
trolled studies [7,9,10]. The model allows for variations in





Figure 1 Overview of the study model.the actual distribution of change as presented in the above
controlled trials.
Healthcare resource use and medication costs
Medication costs were calculated using the latest price
catalogue of medicinal products, as published in the price
bulletin issued by the Ministry of Health (generic prepara-
tions of gabapentin were not included in the analysis due to
their low penetration in the Greek healthcare market).
Moreover, for the purposes of the analysis, it was assumed
that no cost variations would result from prescribing
divided doses of the comparator therapies. The costs
per health service and diagnostic tools were derived
from the official NHS price lists.
To identify healthcare resource utilization data according
to pain severity, a survey, was conducted in a group of 100
general practitioners and 20 specialized pain clinics in
Greece. General practitioners were requested to provide
the percentage of patients that were referred to pain clinics,
according to pain score, whereas data on utilization of
diagnostic tests and other health services arose from the
survey of referable specialized pain clinics (Table 2).
The time frame of interest in the model was twelve
weeks and all NeP-associated direct costs were considered,
and calculated from a third party payer (social insurance)
perspective and reported in year 2011 values.
Sensitivity analyses
To address parameter uncertainty, a series of one-way
sensitivity analyses, were performed, by recalculating the
results, after a ±20% change in baseline values, for selected
Table 2 Probability of healthcare resource use and unit







0 to < 4 0.13 20.00
4 to < 7 0.24 20.00




Nerve conduction studies 0.17 8.63








Physical therapy 0.33 25.00
Drug infiltrations 0.63 20.00
Nerve block 0.39 14.67
TENS 0.36 54.18
Spinal stimulator implant 0.03 4610.90
CAT – computerized axial tomography. MRI – magnetic resonance imaging.
EMG – electromyogram. TENS – transcutaneous electric nerve stimulation.
Physical therapy and drug infiltrations – prices per session.
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pregabalin, the weekly probability of physician visiting
due to NeP and the health utility values in association
with neuropathic pain. Additional scenarios of calcula-







No or mild pain 36 (0.3)
Moderate pain 32 (0.3)
Severe pain 15 (0.2)
Days with
≥30% reduction in pain score 50 (0.3)
≥50% reduction in pain score 36 (0.3)
Quality-adjusted life-years (QALYs) 0.1178 (0.0002)
Results presented as Mean (SE) for the 12 – week duration of modeling.(1800 mg and 1200 mg) as well as the exclusion of non-
medication related health-resource use (i.e. consideration of
medication costs only).
Results
The clinical outcomes at endpoint (t = 12 weeks) are
presented in Table 3. Mean pretreatment pain scores
were identical (6.9) for both pregabalin and gabapentin.
Post-treatment pain score mean values were 4.1 for
pregabalin and 4.8 for gabapentin, with the differences
in the simulations being statistically significant at the
0.05 level. Pregabalin also demonstrated a statistically
significant reduction in days with moderate to severe
pain when compared to gabapentin. That was also apparent
when measuring percentage reduction in pain scores.
During the 12 weeks treatment period, the pregabalin
arm demonstrated a 0.1178 (SE 0.0002) QALY gain,
which proved to be 0.0063 (SE 0.0003) higher than that
in the gabapentin arm (p < 0.05).
The mean medication cost per patient was higher for
the pregabalin arm when compared to the gabapentin
arm (i.e. €134.40 higher) over the 12 week treatment
period. However, as presented in Table 4, this cost was
partially offset by the reduced direct medical costs, such
as the cost of specialist visits, the costs of diagnostic
tests and the other applied interventions, which were
€12 lower Comparing costs with respective outcomes,
the ICERs for pregabalin versus gabapentin were €13
(95%CI: 8 – 18) per additional day with no or mild pain
and €19,320 (95%CI: 11,743 – 26,755) per QALY gained.
Results are summarized in Table 5.
The sensitivity analysis showed that parameters with
the greatest impact on results were the daily cost of
pregabalin and the utilities associated with pain severity
(Table 6). The incremental costs per additional day with
no or mild pain ranged between 7(95%CI: 2, 14) and 24t with Pregabalin or Gabapentin
ent
Gabapentin (2400 mg/d) Difference (Pregabalin - Gabapentin)
6.9 (0,0) 0.0 (0.0)
4.8 (0,0) −0.6 (0.0)
27 (0.3) 9 (0.5)
38 (0.3) −6 (0.5)
19 (0.3) −4 (0.3)
42 (0.4) 8 (0.5)
26 (0.4) 10 (0.5)
0.1115 (0.0002) 0.0063 (0.0003)
Table 4 Expected medical care costs per patient
Treatment
Pregabalin (150–600 mg/d) Gabapentin (2400 mg/d) Difference (Pregabalin - Gabapentin)
Medication 306.60 (0.00) 172.20 (0.00) 134.40 (0.00)
Outpatient care
Primary care provider 36.12 (0.70) 37.45 (0.74) −1.33 (1.04)
Specialist referral 9.89 (0.33) 10.52 (0.33) −0.63 (0.47)
Diagnostic tests 56.86 (3.13) 60.57 (2.90) −3.72 (4.01)
Other interventions 90.88 (18.52) 97.22 (17.12) −6.34 (24.15)
Total 500.35 (19.08) 377.96 (17.73) 122.39 (25.26)
Values in Euros mean (SE).
For the 12 – week treatment period.
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gained ranged between 11,075 (95%CI: 2,944, 23,040)
and 39,073 (95%CI: 28,704, 54,620). Both values refer to
a 20% lowering and a 20% rise, respectively, to the baseline
daily cost of pregabalin. A 1200 mg reduction in the mean
gabapentin daily dose caused the ICER value per QALY
gained to exceed the €30,000 threshold.
Discussion
The present study aimed at estimating the cost-effectiveness
of pregabalin, versus gabapentin for the treatment of DPN
or PHN, taking into account the perspective of a social
security organization in Greece. For that purpose, a pre-
viously presented and validated health economic model
was adapted for the Greek healthcare setting, taking
into account direct costs of treatment and follow up for
a hypothetical cohort of 1,000 patients that were treated
under the two alternatives for a 12 week period, based
on the efficacy profile of each intervention as recorded
in the results of published clinical trials.
The results of the analysis indicate that pregabalin is a
more costly but also a more effective treatment option
compared to gabapentin. The excess costs of pharma-
ceutical treatment for pregabalin are partially offset by
its improved clinical profile in terms of reductions in
resource utilization and its improved outcomes in the pa-
tient level, thus leading to incremental cost-effectivenessTable 5 Incremental cost-effectiveness ratios of
pregabalin vs. gabapentin in the treatment of painful
DPN and PHN
Pregabalin vs Gabapentin
Cost per additional (€) Mean (95% CI)
Day with no or mild pain
Mean estimate 13
95% confidence interval (8, 18)
QALY gained
Mean estimate 19,320
95% confidence interval (11,743 - 26,755)ratios of €13 per additional day with mild/no pain and
€19,320 per QALY gained.
In Greece there are currently no established thresholds
under which interventions can be classified as cost-
effective. In general, the accepted willingness to pay per
QALY gained falls within £20,000 – £30,000 in the UK and
$50,000 – $100,000 in the US [20], whereas older studies in
other healthcare settings have placed this limit at a lower
level (e.g. 20,000$ per QALY gained in Canada [21]). A
generally acknowledged criterion (a “rule of thumb”) states
that interventions costing less than 30,000€/QALY gained
are “good value for money”, from an economic evaluation
point of view [22], a principle that the results of the present
study fulfil. Moreover the study results also meet the
criteria for cost-effective interventions recommended by
the WHO Commission on Macroeconomics and Health
[23]. Specifically, based on the Commission’s recommenda-
tions, interventions with an ICER (expressed in cost per
Disability Adjusted Life Year averted) that is lower than
three times the Gross National Income (GNI) per capita
can be classified as cost-effective, whereas ICERs lower
than 1 ×GNI indicate highly cost effective interventions.
Taking into account a GNI per capita of €19,801 in Greece
(2010 values) and extending the criterion to a per QALY
decision, treatment of painful DPN or PHN with pregabalin
falls within the range of highly cost-effective interventions.
The findings of this study are in accordance to previ-
ously published literature [3,11] that aimed to estimate
the cost – effectiveness of the two pharmacotherapies.
The outcomes of the Rodriguez et al. study in Spain [3]
estimated an ICER (euros per QALY gained and per day
with no or mild pain) of €20,535 (1,607 – 40,345) and
€12 (1 – 24) respectively. The Canadian study of Tarride
et al. [11] examined the two disorders separately and
provided two sets of results, indicating in both cases
that pregabalin was cost-effective. More specifically,
regarding painful DPN, pregabalin had an ICER of $13
per day with no or mild pain and $15,708 per QALY
gained respectively, whereas, for the PHN outcomes
the equivalent values were $3 and $3,325, respectively
Table 6 Sensitivity analysis of the incremental cost effectiveness of pregabalin versus gabapentin in the treatment of
painful diabetic neuropathy and post herpetic neuralgia
Parameter Baseline Sensitivity analysis Cost per additional day
with no or mild pain
Cost per QALY gained
Gabapentin dose (mg) 2400 1800 14 (8,19) 23 786 (14266,33498)
Gabapentin dose (mg) 2400 1200 16 (9,24) 30 241 (18086,44056)
Costs considered All healthcare costs Medication cost only 16 (14,18) 25 683 (22812,29829)
Pregabalin daily cost 3.65 ↑20% 24 (18,34) 39 063 (28704,54620)
Pregabalin daily cost 3.65 ↓20% 7 (2,14) 11 075 (2944,23040)
Weekly probability of PCP visit in relation to NeP No/mild: 0.25 ↑20% 14 (8,20) 21 025 (11592,30710)
Moderate: 0.31
Severe: 0.48
Weekly probability of PCP visit in relation to NeP No/mild: 0.25 ↓20% 13 (7,19) 19 773 (10531,28687)
Moderate: 0.31
Severe: 0.48
Health utility associated with pain severity No/mild: 0.64 ↑20% 13 (9,18) 17 017 (10296,23936)
Moderate: 0.48
Severe: 0.27
Health utility associated with pain severity No/mild: 0.64 ↓20% 14 (8,20) 27 505 (15418,40596)
Moderate: 0.48
Severe: 0.27
Mean values in € (SE) 95% CI.
NeP – Neuropathic pain.
PCP – primary care physician.
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Moreover, the results of this study are in accordance with
findings from a recent systematic review on the effective-
ness and cost-effectiveness of pregabalin in the manage-
ment of DPN . Meshkini et al. (2012) [24] concluded that
higher doses of pregabalin (300 mg – 600 mg daily), appear
highly cost-effective treatment options.
As with any study of its kind, the present one has
some limitations that should be acknowledged. Firstly,
the data on efficacy of the treatments under comparison
are based on clinical trial data, which considered patients
in a different healthcare setting than that in Greece. Thus,
the trial cohorts might not be fully representative for pa-
tients with painful DPN or PHN in Greece, Nevertheless,
the magnitude of this (possible) discrepancy is extremely
difficult to quantify and to include in the calculations of
the analysis. Moreover, the perspective of the analysis
(third-party payer, i.e. the Greek Social Insurance Funds)
does not include other costs, such as the indirect expenses
due to productivity losses. If the societal perspective had
been adopted, there is evidence that the ICERs would
probably be more favourable (i.e. lower). For example, a
recent cost analysis of adding pregabalin or gabapentin to
the management of community – based patients with
peripheral NeP, which estimated also the indirect costs,
showed that although the pharmaceutical costs of
pregabalin were significant, the overall patient cost waslower in the pregabalin group due to reduced sick leave
and lower healthcare costs, and thus was compensated the
higher treatment acquisition cost of pregabalin [25]. A
limitation also arises from the fact that calculations do not
include variations of cost that could arise from divided
dosing regimens due to the design of the model. The same
approach was used in other adaptations of the model, in
different health care settings [3,11].
Another limitation of the analysis that should be
considered is the source of data regarding the resource
use incorporated in the calculations, i.e., the elicitation
of some data via a questionnaire survey. Although an
ideal approach would be to review actual patient data,
the absence of centralized patient records or databases
containing relevant data in the Greek NHS, rendered
necessary the use of a questionnaire survey. Inevitably,
the above mentioned approach introduces uncertainty in
the calculations, whose extent, however, is quite difficult to
quantify. Nevertheless, the magnitude of the study sample,
the simplicity of the data that were requested and the
extensive sensitivity analysis on the baseline values, enhance
the robustness of outcomes.
Finally, the present study concludes that the intervention
under investigation was followed by favourable incremental
cost-effectiveness ratios, compared to other treatment
strategies on pain management. However, the discussion
on the adoption of such a policy by the Social Insurance
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by estimations of this intervention to insurance budgets,
i.e. a budget impact analysis. This issue certainly constitutes
an area of future research.
Conclusion
Neuropathic pain carries a great disease burden for
patients and society and, also, a significant economic
burden. From a third part payer perspective, the treat-
ment of pain associated with painful DPN and PHN
with pregabalin is a cost-effective intervention for the
social security in Greece compared to gabapentin.
Notwithstanding its limitations, the study’s findings
need to be taken into consideration in the decision –
making process when considering which therapy to use
for the treatment of neuropathic pain.
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